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ABSTRACT 
 HRAS, NRAS and KRAS isoforms are almost identical proteins that are ubiquitously 
expressed and activate a common set of effectors. In vivo studies have revealed that 
they are not biologically redundant; however, the isoform-specificity of Ras signaling 
remains poorly understood. Using a novel panel of isogenic SW48 cell lines 
endogenously expressing wild type or G12V mutated activated Ras isoforms we have 
performed a detailed characterization of endogenous isoform-specific mutant Ras 
signaling. We find that despite displaying significant Ras activation, the downstream 
outputs of oncogenic Ras mutants are minimal in the absence of growth factor inputs. 
The lack of mutant KRAS-induced effector activation observed in SW48 cells appears to 
be representative of a broad panel of colon cancer cell lines harboring mutant KRAS. 
For MAP kinase pathway activation in KRAS mutant cells, the requirement for co-
incident growth factor stimulation occurs at an early point in the Raf activation cycle. 
Finally, we find that Ras isoform-specific signaling was highly context dependent and 
did not conform to the dogma derived from ectopic expression studies. 
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INTRODUCTION   
 Ras proteins are ubiquitously expressed monomeric GTPases that represent key 
signaling hubs operating downstream of growth factor receptors to regulate cell 
proliferation, differentiation, protein synthesis, metabolism and cell survival (Pylayeva-
Gupta et al., 2011; Hobbs et al., 2016). Activation of Ras generates a network 
response; however the most intensively studied effector pathways are the Raf-MEK-
ERK and PtdIns 3-kinase (PI3K)-AKT pathways (Cox and Der, 2011). Oncogenic 
mutations in Ras at codons 12, 13 or 61 are present in ~20% of human cancers (Prior et 
al., 2012). Whilst all of these mutations are activating, recent work has indicated that 
each mutation specifies a distinct Ras output and propensity for promoting oncogenesis 
(De Roock et al., 2010; Ihle et al., 2012; Burd et al., 2014; Alamo et al., 2015; 
Hammond et al., 2015; Stolze et al., 2015; Winters et al., 2017). 
 Three ubiquitously expressed Ras genes (HRAS, KRAS and NRAS) encode at least 
4 isoforms that despite being almost identical are not functionally redundant. In vivo 
evidence for this comes from studies of mouse development where KRAS knockout 
mice are embryonic lethal whereas NRAS and HRAS double knockout mice are healthy 
(Koera et al., 1997; Esteban et al., 2001). Mice with HRAS inserted into the KRAS locus 
are viable; however, they exhibit cardiomyopathy that suggests that whilst the patterns 
of expression and gene dosing define the majority of the isoform-specific effects on 
development, there may still be KRAS-specific contributions to healthy development 
(Potenza et al., 2005). Other evidence comes from large-scale profiling of the 
distribution of oncogenic Ras mutations that reveals an isoform-specific bias, with KRAS 
being the most frequently mutated isoform (Prior et al., 2012). Furthermore, 
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comparative studies using mouse models endogenously expressing activated mutant 
Ras isoforms reveal that only KRAS is capable of promoting colonic epithelium 
proliferation (Haigis et al., 2008). 
 The Ras isoform-specific signaling differences underpinning these in vivo differences 
remain poorly understood. Ectopic over-expression studies revealed that whilst all Ras 
isoforms can activate canonical Raf-MAP-kinase and PtdIns 3-kinase (PI3K)-AKT 
pathways, they are differentially coupled. Specifically, KRAS is a better activator of Raf 
and Rac whereas HRAS and NRAS are better activators of PI3K (Yan et al., 1998; 
Voice et al., 1999). Notably however, cells derived from KRAS mutant mouse models 
and cancer cell lines harboring endogenous mutant Ras frequently do not exhibit the 
high levels of PI3K and Raf-MAP kinase pathway activation seen in over-expression 
studies (Iida et al., 1999; Yip-Schneider et al., 1999; Giehl et al., 2000; Tuveson et al., 
2004; Omerovic et al., 2008). Similarly, synthetic lethality studies have illustrated the 
significant context dependence associated with Ras signaling (Downward, 2015). This 
means that any systematic characterization of isoform-specific Ras signaling needs to 
either be based on very large panels of cell lines or performed in isogenic model 
systems where endogenous signaling is measured. 
 Genome edited isogenic cell models allow the study of Ras variants expressed from 
endogenous loci whilst avoiding context-dependent differences associated with different 
genetic backgrounds. The majority of isogenic cell models have used genetic ablation of 
a wild type or oncogenic KRAS allele resulting in some gene dosing differences 
between wild type and oncogenic KRAS cells (Shirasawa et al., 1993; Kim et al., 2004; 
Di Nicolantonio et al., 2008; Yun et al., 2009). More recently, recombinant adeno-
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associated virus (rAAV) targeted genome editing has been used to generate a panel of 
isogenic colorectal SW48 cells harboring a range of heterozygous mutations at codons 
12 or 13 of the KRAS gene (De Roock et al., 2010). Importantly, each individual 
mutation generates a distinct oncogenic and network response (Ihle et al., 2012; Burd et 
al., 2014; Hammond et al., 2015); which means that any comparison of isoform-specific 
oncogenic Ras signaling should incorporate the same activating mutation in each Ras 
gene. Taking this into account we have developed a novel isogenic SW48 cell panel 
and employed a focused network biology strategy to characterize the context-
dependence of endogenous isoform-specific Ras signaling responses.  
 
RESULTS 
An isogenic panel of Ras G12V SW48 cells.  
 To investigate endogenous isoform-specific Ras signaling we generated isogenic 
NRASG12V cell lines to complement an existing panel of heterozygous G12V mutated 
Ras variant SW48 cell lines. The same parental SW48 cells harboring wild type Ras 
isoforms and an rAAV-based genome editing strategy were used for the generation of 
all of the isogenic cell lines used in this study. The presence of an oncogenic Ras 
variant results in no obvious change in the protein abundance of the mutated or wild 
type Ras isoforms in each of the isogenic cell lines (Figure 1A). Highly transforming 
G12V mutations result in constitutive Ras activation and are present in 20% of human 
cancers that possess a mutated Ras (Prior et al., 2012). However, the presence of a 
G12V mutated Ras isoform does not result in noticeable activation of canonical Ras 
effector pathways in the absence of serum where any signaling will be entirely 
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contingent on the mutant Ras proteins (Figure 1B). The lack of response in serum-
starved cells harbouring hyper-active Ras isoforms is in significant contrast to the 
effector activation observed in wild-type cells stimulated for 5 minutes with 15 ng/ml 
EGF (Figure 1B). One explanation for this could be that the absence of growth factors 
reduced nucleotide exchange on Ras to the point where G12V induced resistance to 
GAP-mediated GTP hydrolysis became redundant. However, this does not seem to be 
the case since significant Ras activity is detected for each isoform harboring a G12V 
mutation (Supplementary Figures 1A & 1B).  
 Standard cell culture conditions in the presence of 10% fetal bovine serum (FBS) 
revealed subtle isoform-specific patterns of effector activation, although they do not 
exceed the variability observed between KRASG12V clones (Figure 1C). Therefore, 
mutant Ras activation of effectors is growth factor-dependent, and in the presence of a 
cocktail of growth factors in FBS we found no evidence for isoform specificity of 
endogenous Ras coupling to canonical effector pathways. 
 The variability in some outputs that we observed between the KRASG12V cells raised 
questions about whether our other cells were likely to be representative. We were 
unable to generate additional HRASG12V clones; however, we were able to generate a 
larger panel of NRASG12V clones and observed similar MAPK pathway outputs to the 
clone that we had already selected and some heterogeneity in the AKT pathway 
response. (Supplementary Figure 2). The heterogeneity that we observed within the 
NRASG12V panel was no greater than that observed between the KRASG12V clones.  
Therefore, to acknowledge the potential for clonality to confound our observations we 
have included both KRASG12V clones in all subsequent experiments. Although clonality 
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means that any subtle differences between isoforms are unable to be clearly described, 
all clones show the same growth factor dependence for observing robust activation of 
canonical Ras effector pathways. 
 
Basal downstream signaling is reduced and GF responses are isoform-specific. 
  To characterize the wider network responses of endogenous Ras isoform signaling 
we performed Luminex analysis incorporating phospho-antibody reporters of the 
activation status of 16 relevant downstream and feedback-regulated signaling nodes. 
Cells under basal serum-starved cell culture conditions exhibited no activation of the 
Ras network in the presence of any of the constitutively active Ras isoforms 
(Supplementary Figure 3A). Indeed, all but 5 of the 64 measurements of Ras effector 
phosphorylation are decreased in mutant Ras cells versus wild type Ras Parental cells 
with both KRASG12V clones generally displaying the most pronounced levels of Ras 
network suppression. This may reflect uncoupling of oncogenic Ras from downstream 
signaling and/or adaptive engagement of negative feedback pathways downstream of 
active Ras to suppress the network response.  
 In response to growth factor stimulation Parental as well as G12V mutant cell lines 
exhibit increased activation throughout their Ras network although this is context 
dependent (Figure 1D & Supplementary Figure 3B). Within the RAF-MAP kinase 
pathway the suppressed outputs in Ras mutant cells compared to Parental control are 
generally less evident with co-incident growth factor stimulation. This is particularly clear 
for all isoforms following EGF stimulation and for HGF stimulation of AKT in HRAS and 
KRAS mutant SW48 cells. EGF is the most potent of the three growth factors at 
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activating the Raf pathway (pMEK-pERK-pp90RSK) with for example, 10-15-fold 
increases in MEK activation versus untreated, compared to 2-fold and 4-fold increases 
respectively following HGF and IGF stimulation (Figure 1D & Supplementary Figure 3B). 
In the EGF condition we also see a trend for an additive effect of HRAS for MEK-ERK 
activation. Whilst this suggests enhanced coupling between HRAS and the RAF-MAP 
kinase pathway compared to the other Ras isoforms, this is only present in the context 
of EGF stimulation and not a general feature of HRAS signaling. Notably, Ras activity is 
less stimulatable by EGF if a cell harbors a mutant Ras isoform (Supplementary Figure 
1A & 1C).  
 Within the PI3K pathway the significant suppression of KRAS activation of AKT and 
RPS6 versus Parental control is lost when cells are stimulated with growth factors. 
Strikingly, we observe potent activation of AKT and RPS6 in HGF-stimulated KRAS 
mutant SW48 cells compared to the other cell lines (Figure 1D & Supplementary Figure 
3B). Therefore, analogous to HRAS coupling to the RAF pathway, KRAS coupling to the 
PI3K-AKT pathway is also highly context dependent and not a generic feature of 
endogenous isoform-specific Ras signaling.  
 
Generation of perturbation data to systematically probe signaling.   
 In order to get a deeper understanding, we used a network biology approach where 
responses to pathway manipulations can be used to inform mathematical models that 
predict signaling flow within a network (Klinger et al., 2013). To generate the data for 
mathematical modeling we performed, in addition to the stimulation experiments 
depicted in Figure 1D, a broad range of combinatorial treatments targeting the Ras 
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signaling network (Figure 2A). Specifically, we stimulated the indicated isogenic SW48 
cells for 20 minutes with empirically determined sub-saturating doses of three growth 
factors: EGF, HGF and IGF. The cells had been pre-incubated for 1 hour with 
pharmacological inhibitors of MEK, PI3K, MTOR, Src or solvent control and the 
phosphorylation status of 16 members of the local Ras signaling network was measured 
in a Luminex proteomics platform (Figure 2B, Supplementary Figure 4). The presence 
of inhibitors was maintained whilst co-incident growth factor stimulation was performed. 
The 20 minutes stimulatory time point was chosen because it represented signaling in 
an approximate steady state during the long-term plateau phase that follows the initial 
strong transient peak (Klinger et al., 2013). 
 Whilst generally there are subtle differences between cell lines in response to 
combinatorial treatments, AKT and MEK activation in HGF-stimulated KRAS cells are 
the most obvious outliers (Figure 2B, Supplementary Figure 4). All cell lines show >10-
fold up-regulation of MEK phosphorylation in the presence of MEK inhibitor in EGF-
stimulated cells that would be consistent with the loss of ERK–dependent negative 
feedback.  
 
Modeling unveils subtle interlineal differences and a clear overall effect on 
signaling.  
 Luminex measurements were incorporated into mathematical models of network 
connectivity. We quantified the feed-forward and feedback relationships within a core 
network around Ras in each cell line using mathematical modeling. The algorithm 
determines network structure and parameterizations based on modular response 
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analysis (MRA) (Klinger et al., 2013) (Figure 3A). The model pipeline estimates 
response coefficients for an initial literature-based network and then iteratively edits the 
network to generate the best consensus network for the whole dataset derived from the 
perturbation experiments (Figure 3B point 1 to 2). Afterwards, significantly differing 
parameters across datasets are derived by first modeling all datasets with the same 
parameter set and then iteratively testing if individual fitting of each parameter 
significantly improved the overall fit (likelihood ratio test, p ≤ 0.05). Of the 21 parameters 
tested 10 were required to be fitted specifically to each dataset. Looking at the 
localization of the edges where variability was observed between the Ras mutant SW48 
cells (Figure 3B, point 3) we can see that mainly the upstream signaling is different in 
the cell lines as 5 of the 6 receptor-associated parameters have to be differential 
whereas 8 of the 10 links downstream of ERK and AKT can be modeled with the same 
parameter (dashed links). When looking at the variation size of the differential signaling 
parameters across cell line models (as absolute coefficient of variation (CV)), 3 
parameters (ERK-RAF feedback and MET downstream links) have to be varied strongly 
(CV > 1) whereas the remaining 7 only required minor changes (CV < 0.5). Thus, by 
individually modeling 10 of the total 24 parameters (including the 3 quantifications of 
inhibitor strengths that were not allowed to vary between cell lines) we can simulate cell-
line specific responses that are in good agreement with the experimental data (Figure 
3C). In order to more closely study the differential signaling, we clustered the cell lines 
according to the 10 variable parameters (row-wise normalized to absolute maximum; 
Figure 3D). Whilst most represent relatively subtle differences, in general the KRAS 
clones differentiate from the other cell lines across each of the parameters. The most 
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striking differences are seen for HGF-induced activation of the RAF pathway and 
EGF/HGF/IGF-induced activation of the PI3K pathways that in each case is strongest in 
the KRAS mutant SW48 cells.  
 Apart from modeling individual Ras-isoform-specific models, we also applied a 
holistic model that included all datasets and modeled Ras mutations as perturbations of 
the Parental state. This allowed us to dissect the direct impact of the Ras mutation on 
their downstream outputs, using the previously defined network topology (see Figure 3B 
point 2). We found that all Ras mutations had a negative impact on signaling via PI3K 
and Raf versus Parental cells in each cellular context (Supplementary Figure 4). 
Specifically, we find that basal signaling (in the absence of growth factors) is trending 
downwards in Ras mutant SW48 cell lines and their growth factor inducibility is 
decreased compared to Parental cells. 
 
RASG12V signaling is attenuated upstream of RAF and requires receptor 
stimulation.  
 The network analysis reinforces our earlier observation that active Ras mutants do 
not exhibit potent effector stimulation in the absence of growth factors (Figure 1B), but 
the mechanism remains unclear. To address this, we focused on the Raf-MAP kinase 
pathway and considered each of the points where the signal could be interrupted or 
remodeled (Figure 4A). Phosphorylation of Ser259 on CRAF provides a 14-3-3 binding 
site that stabilizes CRAF in an auto-inhibited state unable to bind to Ras (Lavoie and 
Therrien, 2015). We observed a trend for reduced phosphorylation in the presence of 
growth factors but not RAS mutation alone (Figure 4B). The differences are marginal, 
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and difficult to infer whether there will be consequences in the capacity for mutated RAS 
SW48 cells to recruit Raf to the membrane. However, Raf heterodimerization that 
occurs downstream of Ras recruitment was only seen in the presence of growth factor 
stimulation (Figure 4C). Oncogenically mutated KRAS was unable to promote Raf 
dimerization in the absence of growth factors suggesting either that Raf has not been 
efficiently recruited to the membrane or that dimerization is sensitive to co-incident 
growth factor signaling. Phosphorylation of Ser338 in the catalytic domain of CRAF 
indicates a fully active Raf molecule (Lavoie and Therrien, 2015). Clear growth factor 
dependence is seen for activating phosphorylation of CRAF and downstream effectors 
(Figure 4D & 4E). Finally, we explored whether negative feedback was actively down-
regulating mutant RAS signaling. Negative feedback phosphorylation of Ser289/296/301 
on CRAF is mediated by activated ERK (Lavoie and Therrien, 2015), and we saw clear 
sensitivity of these sites to MEK inhibition following EGF stimulation but not in the 
starved condition when any MEK-ERK activation would be driven exclusively by mutant 
RAS (Figure 4F, Supplementary Figure 5). Therefore, the low levels of MEK-ERK 
phosphorylation seen in mutant RAS SW48 cells in the absence of growth factor 
stimulation are not a cause or consequence of negative feedback to CRAF. Together, 
these data demonstrate that oncogenically mutated RAS in our cells is unable to 
activate the Raf-MAP kinase pathway in the absence of co-incident growth factor 
stimulation and that the requirement for growth factors is evident from early in the Raf 
activation cycle. 
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Oncogenic Ras decoupling from effector pathways is also observed in a wider 
colorectal cancer cell panel. 
 There are no independent isogenic systems with equivalent mutations in each of Ras 
isoforms that we could use to increase confidence in the wider applicability of our 
findings. Instead we assembled a panel of colorectal cancer cell lines variously 
containing mutations in Ras pathway components (Figure 5A). Quantitation of Western 
blots from biological replicates reveals that KRAS mutation status does not define the 
effector response and co-clustering of mutant and wild-type KRAS cell lines is observed 
(Figure 5B). Notably, there is no evidence of effector stimulation in a subset of KRAS 
mutant cell lines with only 7/11 pMEK and 6/11 pAKT responses in KRAS mutant cells 
displaying increased phosphorylation versus wild type SW48 cells and only 1/11 KRAS 
mutant cell lines showing strong pAKT increases (Figure 5A). This is consistent with the 
observations in the SW48 cell panel where the presence of mutated Ras did not lead to 
AKT or MEK phosphorylation in the serum-starved context (Figure 1B). We confirmed 
that the KRAS mutations are functional with all codon 12, 13 and 61 mutants exhibiting 
clear increases in KRAS activity compared to the wild type KRAS cell lines (Figure 5B). 
The A146T mutation that is observed in <0.05% of colon cancers had a negligible effect 
on LIM1215 cell KRAS activity. A lack of correlation between the amount of KRAS 
activity and effector activation is seen regardless of the presence or absence of co-
incident mutations (Figure 5C). Similarly, in a wider Luminex-based analysis of Ras 
network activation we see that mutation status does not define the co-clustered 
responses, with the exception of pMEK responses in BRAF mutant cells (Figure 5D), 
and this data reemphasizes that cells with KRAS mutations show no general trend of 
 14 
increased signaling. In summary, data generated using the SW48 panel are consistent 
with a subset of colon cancer cell lines harboring mutant KRAS that also exhibit 
negligible effector activation in the absence of growth factors despite harboring 
activated KRAS. 
  
DISCUSSION 
 Isoform-specific Ras signaling has been inferred from studies of mouse development 
and cancer mutation frequencies (Koera et al., 1997; Esteban et al., 2001; Prior et al., 
2012); however, we still only have a vague understanding of the isoform-specific 
mechanisms that may underpin this. Classic studies ectopically expressing Ras 
isoforms suggested clear differences in coupling of RAF and PI3K pathways to Ras 
isoforms (Yan et al., 1998; Voice et al., 1999; Hobbs et al., 2016). Whilst amplification of 
Ras is observed in some tumours, it is also true that over-expression can have 
distorting effects on signaling networks and senescence rather than an oncogenic 
program is observed in some Ras models (Sarkisian et al., 2007). Isogenic cells provide 
a useful option for studying variants of endogenous signaling networks without being 
confounded by differences in the genetic backgrounds of the various cell lines. To date, 
isogenic cell-based studies have largely focused on comparative analysis of KRAS 
mutant versus wild type Ras cells (Vartanian et al., 2013; Alamo et al., 2015; Stolze et 
al., 2015). Given the clear evidence for Ras mutation-specific signaling (Burd et al., 
2014; Hammond et al., 2015; Winters et al., 2017), we used the same G12V mutation in 
all three Ras isoforms. This novel cell line panel means that we have been able to 
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perform the first analysis of endogenous isoform-specific Ras signaling in the same 
genetic background. 
 A notable initial observation was the general inability of G12V-mutated Ras isoforms 
to generate enhanced RAF and PI3K pathway signaling outputs compared to the wild 
type control (Figure 1B). G12V mutant Ras displays slow nucleotide exchange and slow 
GTP hydrolysis (Trahey et al., 1987; Smith et al., 2013), meaning that starvation and 
stimulation times could significantly influence the amount of active Ras in the cell. 
However, under the conditions in which we performed the experiments it was clear that 
the lack of effector activation was not due to a lack of Ras activation (Supplementary 
Figure 1A). It is relevant to note that SW48 cells harbor an EGFRG719S mutation that has 
been observed to promote ligand-independent EGFR kinase activity and Ras effector 
activation (Greulich et al., 2005); and might be expected to exhibit pre-existing 
engagement of negative feedback pathways. However, we saw no evidence for this 
under our experimental conditions; all of the isogenic cell lines showed significant EGF 
stimulatability, effector activation was minimal under serum-starved conditions and 
negative feedback was only consistently observed when EGF was added to cells 
(Supplementary Figure 5). 
 One potential criticism of our cell model is that the introduction of Ras oncogenic 
mutations into a wild type Ras SW48 cell parental background does not result in Ras 
addiction that is observed in some cancer cell lines in some contexts. Therefore, the 
signaling that we are observing may not be equivalent to “true” oncogenic mutant Ras 
signaling. In fact, DepMap analysis reveals that <30% of 2-D cultured KRAS mutant cell 
lines show strongly selective KRAS dependence (Tsherniak et al., 2017). Furthermore, 
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our observation of low levels of effector activation in Ras mutant SW48 cells has been 
seen before in a range of Ras mutant cancer cells and mouse models (Iida et al., 1999; 
Yip-Schneider et al., 1999; Giehl et al., 2000; Tuveson et al., 2004; Omerovic et al., 
2008; Vartanian et al., 2013). We also observed a disconnect between the presence of 
activating KRAS or PIK3CA mutations and activation of their effector pathways in a 
panel of colon cancer cell lines commonly used to study KRAS and cancer biology 
(Figure 5). Our observations of Ras versus effector activation seen in the wild type and 
KRAS mutant SW48 cells sat well within the range of observations seen within the 
representative panel of colon cancer cell lines. Together, these argue against any 
exceptionalism for the isogenic SW48 model and the subtle effects on downstream 
signaling that are observed in the Ras mutant cells. 
 Importantly, studies across a wide range of Ras mutant cell models have usually not 
had access to an equivalent matched wild type Ras cell line for comparison so it has not 
generally been obvious that mutations that generate hyper-activated Ras can fail to 
result in enhanced outputs compared to wild type Ras. It may be that the chronic trickle 
of low-level effector activation represents the reality of oncogenic signaling until the 
acquisition of genetic insults that further dysregulate signaling later in the progression of 
the cancer. Indeed, this low level signaling may be important for avoiding pushing the 
cells into cytotoxic stress, cell death or senescence (Varmus et al., 2016). 
 Stimulation with growth factors potently activated Ras effectors (Figures 1 & 2); 
therefore, the lack of signaling seen in the Ras mutant cells was not due to a complete 
down-regulation or uncoupling of the Ras network. The second feature of the growth 
factor stimulation experiments was that Ras isoforms variably display enhanced 
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coupling to the RAF and PI3K pathways (Figure 1D). However, these were not 
consistent across all growth factor stimulations (Figure 2) and the patterns did not 
conform to the observations seen in ectopic expression studies where KRAS 
preferentially coupled to Raf-MAP kinase and HRAS coupled to the PI3K pathway (Yan 
et al., 1998; Voice et al., 1999). Therefore, the dogma that Ras isoforms consistently 
favor coupling to a particular Ras pathway is incorrect in this endogenous context and 
the reality is far more nuanced and subject to growth factor modulation. 
 Mathematical modeling of the combinatorial treatment data revealed that the core 
signaling networks are very similar between the Ras isoforms (Figure 3). Nevertheless, 
there were some significant differences between the Ras isoforms that tended to 
distinguish the KRAS cell lines from the rest. The most pronounced of these differences 
were the increased GF-induced pathway activation (Figure 3D). HGF was particularly 
selective for KRAS-dependent PI3K pathway activation and this observation can be 
explained by the increased expression of the HGF receptor MET in KRAS mutant cell 
lines including both G12V clones (Hammond et al., 2015). Although MET is upstream of 
KRAS, it has a well-established role in Ras-dependent tumorigenesis that typically 
involves gene and protein amplification consistent with our observations (Webb et al., 
1998; Furge et al., 2001; Xie et al., 2012; Hammond et al., 2015).   
 Importantly, the modeling did not point to a profound rewiring of the Ras network that 
could explain the minimal effector activation in the absence of growth factors. Similarly, 
our experiments to profile where the signaling downstream of Ras might be interrupted 
revealed no evidence for network rewiring. Instead, they suggested that mutant Ras in 
serum-starved cells was unable to efficiently activate Raf (Figure 4), arguing that growth 
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factor signaling is required to give competence to Ras activation of this key effector 
pathway. Insufficiency may arise due to the coordinated regulation of kinases, 
phosphatases, scaffolds and cofactors required for Raf-MAPK activation (Figure 4A) 
(Lavoie and Therrien, 2015). In this context, growth factor receptor engagement of a 
wider signaling network than Ras could be required to create a permissive state for 
efficient Ras signaling. We note that ectopic expression studies have shown 
downstream activation in serum-starved cells when Ras mutants are over-expressed 
(Yan et al., 1998; Voice et al., 1999). Whilst this could argue against Ras insufficiency, 
an alternative interpretation is that the higher concentration of Ras in cells is able to 
overcome the requirement for growth factor signaling to prime the Ras network. Higher 
Ras concentrations will influence the nanoscale organization of Ras on the plasma 
membrane and increase the opportunity for dimerization and interactions with effectors 
(Zhou et al., 2017). Alternative explanations for the requirement for growth factors could 
include a requirement for SOS recruitment and wild type Ras engagement (Margarit et 
al., 2003; Jeng et al., 2012), that alternative effectors may be preferentially bound in the 
absence of growth factors (Adhikari and Counter, 2018), or that nucleotide cycling within 
the Ras population may be required for efficient and disease-relevant signaling (Nichols 
et al., 2018; Ruess et al., 2018). 
 An important caveat with these studies is the use of a single isogenic cell model 
system and the potential for cell clonality to confound the observations. To give an 
indication of potential clonal heterogeneity we profiled a panel of NRAS clones to 
identify a representative clone (Supplementary Figure 2) and used more than one 
KRAS clone throughout our studies. Whilst it is clear that heterogeneity between clones 
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exists, all of the clones conformed to the core observations of minimal effector 
responses to the presence of mutant Ras and similar substantial context-dependent 
responses to the presence of different growth factors. We also observe similar mutant 
KRAS-refractory responses in a representative panel of colon cancer cell lines. Whilst 
data from a single isogenic system is not definitive, our observations challenge current 
models and highlight fundamental aspects of Ras biology requiring further 
understanding. 
 In summary, we have created an isogenic cell panel that for the first time allows 
endogenous signaling of all Ras isoforms to be investigated in a common genetic 
background. The expression of isoform-specific G12V mutant Ras in the background of 
five wild type Ras alleles, all expressed in their native genomic contexts, represents the 
earliest stage of Ras-driven cancer. The observed limited activation of key effector 
pathways suggests that endogenous oncogenic Ras signaling relies on co-stimulatory 
events or further genetic perturbations to overcome cellular homeostasis mechanisms. 
These mechanisms are imposed at the earliest points in the effector activation cycle. 
Differences between Ras isoform outputs were most clearly revealed with concomitant 
growth factor stimulation where it operated as a subtle but variable nudge on the 
significant growth factor-induced program. This is likely to be critical in the context of the 
tumour microenvironment where mutated Ras will operate in the presence of a cocktail 
of growth factors. Our systematic analysis reveals that the long-held view that Ras 
isoforms are consistently coupled to particular effector pathways is likely to be over 
simplistic and that the context dependence of HRAS, NRAS and KRAS signaling 
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precludes any general predictions of likely pathway activation in response to a specific 
isoform. 
 
 
MATERIALS AND METHODS 
Reagents. The following inhibitors were used in various assays: AZD6244 (5µM; MEK; 
Selleck Chemicals), LY294002 (20µM; PI3K; Alexis Chemicals), Rapamycin (0.15µM; 
TOR; Selleck Chemicals), Dasatinib (25 nM; Src; Selleck Chemicals). The solvent 
control was DMSO (equal volume to each inhibitor). The following ligands were used (all 
Peprotech): IGF-1 (50 ng/ml), EGF (15 ng/ml) and HGF (50 ng/ml) with 0.1% BSA in 
PBS as solvent.  
 
Cell lines. Ras mutation sequence verified isogenic SW48 cells were obtained from 
Horizon Discovery. The clones used were HRASG12V (clone 1), KRASG12V (clone c16 
(K1) and clone c48 (K2)). Heterozygous knock-in of NRASG12V (clone G9-1 (N1), clone 
7-2 (N2), clone 4-2 (N3), and clone 8-1 (N4)) was generated from homozygous RASWT 
Parental SW48 cells, using AAV-mediated gene editing and sequence verified for the 
presence of a heterozygous NRAS G12V mutation. SW48 cells were grown in McCoy’s 
5A media, supplemented with 10% [v/v] FBS, 100 units/ml penicillin and 100 µg/ml 
streptomycin (Thermo Fisher Scientific), at 37ºC in 5% [v/v] CO2. The colon cancer cell 
panel comprising Caco-2, LIM1215, Colo205, Vaco432, RKO, SW837, Colo678, LS180, 
SW480, SW620, LoVo, T84, HCT8, HCT116, SW948 were cultured in DMEM (BE12-
707F, Lonza/Biozym), supplemented with 1%Ultraglutamine (BE17-605E/U1, 
Lonza/Biozym), 100 units/ml penicillin and 100 µg/ml streptomycin (DE17-602E, 
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Lonza/Biozym) and 10% [v/v] FBS (P30-1506, PAN Biotech) at 37°C and 5% CO2. 
Vaco432 cells were obtained from René Bernards lab (NKI), all other cell lines from AG 
Sers (Charité). All cell lines were Short tandem repeat (STR)-authenticated via Eurofins 
Genomics. Vaco432 could not be matched, as they were not found in the database. 
Mycoplasma testing was conducted by Eurofins Genomics. 
 Starvation of cells was done for 16h with FBS-free medium, before lysis. Lysis was 
done with the lysis Buffer from the Ras activation assay and protease inhibitors there 
included. For WB lysates, protease- and phosphatase inhibitors from Bio-Plex Cell Lysis 
Kit (Biorad ,171-304012) were used. Protein concentration was determined using BCA 
Protein Assay Kit (Pierce™,23227). After SDS-PAGE, proteins were blotted to 
nitrocellulose membranes and stained with Pierce™ Reversible Protein Stain Kit, wich 
was later used for normalisation. The following Abs were used: Rabbit anti-pMEK 
(CST9154), Rabbit anti-pAkt T308 (CST9275), Rabbit anti-pAkt S473 (CST4060), 
Rabbit anti-pERK (CST4370), Mouse anti-pERK (CST9106). The blots were imaged 
with Odyssey CLx and infrared labelled antibodies (all Li-Cor). Analysis was done using 
ImageJ after exporting pictures from ImageStudio (Li-Cor). 
 
Luminex assays. Cell lysates were prepared using the Bio-Plex Pro™ Cell Signaling 
Reagent Kit (Bio-Rad), according to manufacturer’s instructions. Briefly, cells seeded 
into 24 well plates were serum starved for 24 hours then incubated ±inhibitors in serum-
free media for 1 hour, followed by a 20 minute stimulation ±growth factor in the 
continued presence of inhibitor. Lysates were measured with a Bio-Plex Protein Array 
(Bio-Rad, Hercules, CA) as described earlier (Klinger et al., 2013) using magnetic bead-
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based ELISAs specific for phospho-AKTS473 (171-V50001M), phospho-c-JunS63 (171-
V50003M), phospho-EGFRY1068 (171-V50004M), phospho-ERK1/2T202,Y204/T185,Y187 (171-
V50006M), phospho-GSK3A/BS21/S9 (171-V50007M), phospho-IkBaS32,S36 (171-
V50010M), phospho-JNKT183,Y185 (171-V50011M), phospho-MEK1S217,S221 (171-
V50012M), phospho-mTORS2448 (171-V50033M), phospho-p38T180,Y182 (171-V50014M), 
phospho-p53S15 (171-V50034M), phospho-PI3KY458 (171-V50036M), phospho-
RPS6S235,S236 (171-V50038M), phospho-p90RSKS380 (171-V50035M), phospho-
SMAD2S465,S467 (171-V50019M) and phospho-SrcT416 (171-V50039M). The capture 
antibody-coated beads as well as detection antibodies and the fluorescent conjugate 
SAPE were diluted 1:3. We used the R package lxb for data acquisition and normalized 
the data as described in Supplemental File 1. Statistical testing on excerpts of the 
luminex assay (i.e. Figure 1D, Supplementary Figure 3) was conducted by applying a 
one-way-ANOVA (analysis of variance) on logarithmized data of each subplot followed 
by multiple correction testing (Benjamini-Hochberg). For significant findings (FDR≤0.05) 
a post-hoc analysis was conducted (Tukey’s Honestly Significant Difference test) to 
report adjusted p-values for the comparisons of interest. 
 
Model construction and evaluation. The modeling procedure relies on a variant of 
modular response analysis (MRA) (Klinger et al., 2013) that quantifies identifiable 
parameter (combinations) of a given network structure on base of systematic 
perturbation data. The network structure was derived from available literature and prior 
modelling approaches of colorectal cancer cell lines (Klinger et al., 2013). Modeling was 
conducted in the two steps network structure determination and differential signaling 
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detection: (1) Five cell line-specific models were generated based on the literature 
network choosing the best of 3x104 sample runs, observing that the ranked fits 
converged on the lower end and multiple best fits were found. These data sets were 
then locally adjusted to the data by determining superfluous links, i.e. removal did not 
significantly decrease the fit (likelihood-ratio test p>0.05), and missing links, i.e. 
addition, significantly improved the fit (Benjamini-Hochberg corrected p≤0.05) in all five 
cell lines. Among the extension candidates only those were included, for which a 
biological confirmation could be found in the literature (e.g. PI3K -> Raf). (2) The 
generated consensus network was then used to train a modelset (4x104 simulations) 
which models the individual data sets by a single parameter set. In order to determine 
significantly differing parameters, modelset parameters were iteratively relaxed to fit cell 
line-specific data (i.e. a split up of one parameter into five) in a greedy hill parameter 
splitting procedure with ensuing reverse lumping procedure (likelihood-ratio test p≤0.05, 
best of 10³ simulations each). 
 The holistic model (Supplementary Figure 4) used the found consensus network 
above but treated Ras mutations as perturbations of the parental dataset, essentially 
modelling all datasets by one model with nodes of the Ras mutations added and each 
linked to RAF and PI3K (105 simulations). The model was run on either the whole 
dataset or on datasets without stimulations. All modeling steps were conducted using 
the R package STASNet (Version 1.0.0) available under 
https://github.com/molsysbio/STASNet 38 as described in Supplemental File 2.  
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Ras activation assay and co-immunoprecipitation. Ras activity assays were 
performed as described using the Ras Activation Assay Kit (Cytoskeleton, BK008). 
Briefly, cells were serum starved for 24 hours, before incubation ±15 ng/ml EGF for 20 
minutes, lysis and incubation of 300µg of pre-cleared lysate with 30 μl (100 μg) GST-
Raf1-RBD-conjugated sepharose beads for 1 hour at 4 ˚C with rotation. Controls using 
serum-starved SW48 Parental cell lysates incubated with 1-3 mM GDP (100% inactive 
Ras), and 200 µM GTPS (100% active Ras) were included for comparative 
normalisation of cell lines. For co-immunoprecipitation, cell lysates were prepared using 
NP40 lysis buffer (50 mM Tris-HCl, pH7.5, 150 mM NaCl, 1 % NP40 substitute protease 
inhibitor cocktail (P8465; Sigma), phosphatase inhibitor cocktail (PhosStop; Roche), 2 
mM NaF).  1.5 mg lysate was pre-cleared with protein A-conjugated agarose (Sigma) 
then incubated with 2 μg BRAF antibody (Santa Cruz sc-5284) or normal mouse IgG 
Control (EMD Millipore, 12-371) and 7.5 μl (4.5 mg) Protein A agarose, for 2.5 hours. 
Beads from activity/co-precipitation experiments were washed and then boiled in 
sample buffer to elute proteins for loading on 4-12% NuPAGE Bis-Tris gels and 
visualisation by Western blotting. The following primary antibodies were used for 
Western blotting including for experiments measuring isoform-specific Ras activity; 
rabbit monoclonal pan-RAS (52939) phospho-CRAFS259 (173539; both AbCam), KRAS 
(Life Span Biosciences LS-C175665), HRAS (sc-520), NRAS (sc-31), BRAF (sc5284), 
EGFR sc-03; all Santa Cruz), CRAF (9422), phospho-CRAFS289/S296/S301 (9431), 
phospho-CRAFS338 (9427), MEK (9122), phospho-MEKS217/S221 (9154), ERK (4695), 
phospho-ERK1/2T202/Y204 (4370), AKT (9272), phospho-AKTS473 (4060), phospho-
EGFRY1068 (2234), actin (6276; all Cell Signaling Technology).  
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Figure 1.  Context-dependent activation of canonical Ras effectors by endogenous Ras 
isoforms. (A) Ras isoform protein expression is similar to Parental (P) control in all 
isogenic cell lines. (B) The presence of an oncogenic RasG12V allele is insufficient to 
activate effector pathways in the absence of co-incident growth factor stimulation. (C) 
There are no clear isoform-specific effects on effector activation in response to cell 
culture in the presence of 10% FBS. Western blotting data representative of n≥3 
biological replicates. (D) Luminex-based measurement of key nodes within the Ras 
signaling network in untreated and growth factor-stimulated cells reveals that differential 
coupling of Ras isoforms with the RAF (pMEK, pERK, pp90RSK) or PI3K PI3K (pAKT, 
pMTOR, pRPS6) pathways is not a generic feature of Ras signaling; mean ±SD of n=2 
biological replicates. p-values correspond to Tukey’s test (versus Parental) for those 
cases where multiple testing corrected one-way-ANOVA was significant (FDR≤0.05); * 
p<0.05, **, p<0.01, *** p<0.001. 
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Figure 2. Generation of systematic perturbation data. (A) Schema depicting stimulated, 
inhibited and measured nodes within the Ras signaling network that were used for 
generation of systematic perturbation data. (B) Log2-fold changes (FC) of 
phosphorylation in response to combinations of growth factor stimulation and node 
inhibition across the 5 isogenic SW48 cells lines measured with Luminex-based 
phospho-assays are displayed. Values are averaged signals from n=2 biological 
replicates normalized to the untreated Parental cell line control (BSA treated control 
lane).  
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Figure 3. Model fit reveals Ras isoform-specific differences in network topology. (A) 
Workflow of modeling steps to determine differential signaling based on Modular 
Response Analysis (MRA). (B) Realization of modeling steps from A: the starting 
network, consensus network with pruned (red) and extended (blue) links (chi2-test, 
p≤0.05) and the resultant differential signaling network of which the numbers and line 
width reflect differential signaling across the five cell lines as absolute coefficient of 
variation (CV) of the parameter quantifications and dashed links denote unvaried links. 
(C) Side-by-side comparison of experimental data (black) and model simulations 
(yellow) derived from the final model (step 3 in B). (D) Clustered heatmap of the variable 
network parameters with each row scaled by the absolute maximal value.  
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Figure 4. Oncogenically mutated Ras requires co-incident growth factor stimulation to 
activate Raf. (A) The Raf activation cycle. (B) RAF auto-inhibitory phosphorylation is 
largely unchanged by Ras mutation. (C) Growth factor dependence is observed with 
BRAF:CRAF heterodimerization, (D) Activating phosphorylation of the CRAF kinase 
catalytic domain, (E) downstream activation of CRAF effectors, and (F) ERK-mediated 
negative feedback to CRAF revealed by decreased CRAF phosphorylation in the 
presence of MEK inhibitors. All blots are representative of n≥3 biological replicates. 
Graphs depict mean values ±SEM; paired, equal variance t-test versus Parental cells or 
indicated pair-wise comparisons, * p<0.05, ** p<0.01, *** p<0.001, n=3 biological 
replicates. Cells starved for 24 hours (EGF -), ±15ng/ml EGF stimulation (EGF +) for 5 
minutes for all experiments except 20 minutes for feedback experiment. 
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Figure 5. Ras effector activation does not correlate with KRAS mutation status in a 
panel of colon cancer cells. (A) Mutation status of a representative panel of colorectal 
cancer cell lines. Representative Western blots from n=2-4 biological replicates indicate 
that the presence of an oncogenic mutation is not necessarily leading to activation of 
effector pathways in the absence of co-incident growth factor stimulation. (B) 
Quantification of KRAS activity measured using a Raf RBD assay (see (A) for 
representative blot) indicates that codon 12, 13 and 61 mutant cells contain activated 
KRAS (mean ± SEM; n=3). (C) KRAS activity does not correlate with ERK and AKT 
phosphorylation. (D) Luminex-based measurement of key nodes within the Ras 
signaling network reveals that responses do not strictly co-cluster based on mutation 
status. Values are averaged signals from n=2-6 biological replicates normalized to the 
SW48 cells. In all experiments, cells were starved for 16 hours prior to assaying. 
 
